Zhang Luodan, Zeng Fa, Jiang Minmin, Han Maozhen, Huang Binbin
Department of Nephrology, Anhui Provincial Children's Hospital, Children's Hospital of Anhui Medical University, Hefei, Anhui, China.
Shenzhen Longhua Maternity and Child Healthcare Hospital, Shenzhen, Guangdong, China.
Front Cell Dev Biol. 2022 Nov 3;10:1005681. doi: 10.3389/fcell.2022.1005681. eCollection 2022.
Endocrine and metabolic diseases show increasing incidence and high treatment costs worldwide. Due to the complexity of their etiology and mechanism, therapeutic strategies are still lacking. Osteoprotegerin (OPG), a member of the tumor necrosis factor receptor superfamily, appears to be a potential candidate for the treatment of these diseases. Studies based on clinical analysis and rodent animal models reveal the roles of OPG in various endocrine and metabolic processes or disorders, such as bone remodeling, vascular calcification, and β-cell proliferation, through the receptor activator of nuclear factor kappa-B ligand (RANKL) and the receptor activator of NF-κB (RANK). Thus, in this review, we mainly focus on relevant diseases, including osteoporosis, cardiovascular disease (CVD), diabetes, and gestational diabetes mellitus (GDM), to summarize the effects of the RANKL/RANK/OPG system in endocrine and metabolic tissues and diseases, thereby providing a comprehensive insight into OPG as a potential drug for endocrine and metabolic diseases.
内分泌和代谢性疾病在全球范围内的发病率不断上升，治疗成本高昂。由于其病因和机制复杂，目前仍缺乏有效的治疗策略。骨保护素（OPG）是肿瘤坏死因子受体超家族的成员之一，似乎是治疗这些疾病的潜在候选药物。基于临床分析和啮齿动物模型的研究表明，OPG通过核因子κB受体活化因子配体（RANKL）和核因子κB受体活化因子（RANK），在各种内分泌和代谢过程或疾病中发挥作用，如骨重塑、血管钙化和β细胞增殖。因此，在本综述中，我们主要关注包括骨质疏松症、心血管疾病（CVD）、糖尿病和妊娠期糖尿病（GDM）在内的相关疾病，总结RANKL/RANK/OPG系统在内分泌和代谢组织及疾病中的作用，从而全面了解OPG作为内分泌和代谢性疾病潜在药物的情况。
